Anita Varma and Chuck Larsen, White & Case

6 December 2017Big Pharma

LSPN Europe 2017: PTAB facing criticism over political independence

A lawyer speaking at the Life Sciences Patent Network (LSPN) Europe conference has said the US Patent Trial and Appeal Board (PTAB) has come under fire for not being politically independent.

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

WATCH: Clinical trials and their impact on patentability in Europe